Solid Biosciences (SLDB) Stock Forecast, Price Target & Predictions
SLDB Stock Forecast
Solid Biosciences stock forecast is as follows: an average price target of $17.50 (represents a 120.68% upside from SLDB’s last price of $7.93) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
SLDB Price Target
The average price target for Solid Biosciences (SLDB) is $17.50 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $20.00 to $12.00. This represents a potential 120.68% upside from SLDB's last price of $7.93.
SLDB Analyst Ratings
According to 7 Wall Street analysts, Solid Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for SLDB stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Solid Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 24, 2024 | Joseph Schwartz | Leerink Partners | $12.00 | $6.62 | 81.27% | 51.32% |
| May 31, 2024 | Biren Amin | Piper Sandler | $20.00 | $7.64 | 161.78% | 152.21% |
| May 16, 2024 | Gena Wang | Barclays | $18.00 | $9.69 | 85.76% | 126.99% |
| Mar 13, 2024 | Christopher Raymond | Raymond James | $20.00 | $12.23 | 63.53% | 152.21% |
The latest Solid Biosciences stock forecast, released on Jun 24, 2024 by Joseph Schwartz from Leerink Partners, set a price target of $12.00, which represents a 81.27% increase from the stock price at the time of the forecast ($6.62), and a 51.32% increase from SLDB last price ($7.93).
Solid Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 4 |
| Avg Price Target | - | $12.00 | $17.50 |
| Last Closing Price | $7.93 | $7.93 | $7.93 |
| Upside/Downside | -100.00% | 51.32% | 120.68% |
In the current month, the average price target of Solid Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Solid Biosciences's last price of $7.93. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 14, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 24, 2024 | Leerink Partners | - | Outperform | Upgrade |
| Jun 21, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 16, 2024 | Barclays | Overweight | Overweight | Hold |
| Mar 28, 2024 | William Blair | - | Outperform | Initialise |
| Mar 13, 2024 | Piper Sandler | Neutral | Overweight | Upgrade |
| Apr 28, 2022 | Piper Sandler | Neutral | Neutral | Hold |
| Apr 28, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Apr 28, 2022 | Chardan Capital | Buy | Buy | Hold |
Solid Biosciences's last stock rating was published by H.C. Wainwright on Aug 14, 2024. The company gave SLDB a "Buy" rating, the same as its previous rate.
Solid Biosciences Financial Forecast
Solid Biosciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $6.17M | $1.93M | $3.15M | $3.54M | $3.59M | $3.33M |
| Avg Forecast | - | - | - | - | - | - | - | $446.18K | $404.70K | $404.70K | $404.70K | $1.45M | $1.10M | $1.47M | $2.20M | $2.20M | $300.00K | $4.08M | $2.68M | $1.73M | $2.13M | $2.82M | $4.22M |
| High Forecast | - | - | - | - | - | - | - | $446.18K | $404.70K | $404.70K | $404.70K | $1.45M | $1.10M | $1.47M | $2.20M | $2.20M | $300.00K | $4.08M | $2.68M | $1.73M | $2.13M | $2.82M | $5.07M |
| Low Forecast | - | - | - | - | - | - | - | $446.18K | $404.70K | $404.70K | $404.70K | $1.45M | $1.10M | $1.47M | $2.20M | $2.20M | $300.00K | $4.08M | $2.68M | $1.73M | $2.13M | $2.82M | $3.38M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | 1 | 2 | 1 | 1 | 1 | - | 5 | 11 | 12 | 11 | 10 | 13 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.51% | 0.72% | 1.82% | 1.66% | 1.28% | 0.79% |
Solid Biosciences's average Quarter revenue forecast for Sep 22 based on 0 analysts is $300.00K, with a low forecast of $300.00K, and a high forecast of $300.00K. SLDB's average Quarter revenue forecast represents a -95.14% decrease compared to the company's last Quarter revenue of $6.17M (Jun 22).
Solid Biosciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | 1 | 2 | 1 | 1 | 1 | - | 5 | 11 | 12 | 11 | 10 | 13 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-21.68M | $-23.11M | $-26.27M | $-30.95M | $-20.69M | $-21.62M | $-24.66M | $-17.85M | $-17.23M | $-17.98M | $-16.17M |
| Avg Forecast | - | - | - | - | - | - | - | $89.24K | $80.94K | $80.94K | $80.94K | $290.00K | $220.00K | $293.40K | $440.00K | $440.00K | $-21.95M | $816.90K | $-19.15M | $346.45K | $426.96K | $563.28K | $-20.46M |
| High Forecast | - | - | - | - | - | - | - | $89.24K | $80.94K | $80.94K | $80.94K | $290.00K | $220.00K | $293.40K | $440.00K | $440.00K | $-17.56M | $816.90K | $-15.32M | $346.45K | $426.96K | $563.28K | $-16.37M |
| Low Forecast | - | - | - | - | - | - | - | $89.24K | $80.94K | $80.94K | $80.94K | $290.00K | $220.00K | $293.40K | $440.00K | $440.00K | $-26.34M | $816.90K | $-22.98M | $346.45K | $426.96K | $563.28K | $-24.55M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -98.54% | -78.78% | -59.70% | -70.35% | 0.94% | -26.47% | 1.29% | -51.52% | -40.36% | -31.91% | 0.79% |
undefined analysts predict SLDB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Solid Biosciences's previous annual EBITDA (undefined) of $NaN.
Solid Biosciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | 1 | 2 | 1 | 1 | 1 | - | 5 | 11 | 12 | 11 | 10 | 13 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-20.34M | $-20.98M | $-24.63M | $-28.11M | $-19.69M | $-24.80M | $-25.28M | $-18.61M | $-17.98M | $-18.70M | $-16.90M |
| Avg Forecast | $-28.15M | $-26.85M | $-25.91M | $-26.25M | $-30.70M | $-29.39M | $-28.49M | $-28.16M | $-28.32M | $-27.35M | $-27.17M | $-26.18M | $-41.89M | $-48.40M | $-56.09M | $-65.97M | $-22.90M | $-133.04M | $-19.70M | $-122.80M | $-109.65M | $-106.65M | $-21.39M |
| High Forecast | $-28.15M | $-26.85M | $-25.91M | $-26.25M | $-30.70M | $-29.39M | $-28.49M | $-28.16M | $-28.32M | $-25.71M | $-27.17M | $-26.18M | $-22.40M | $-48.40M | $-56.09M | $-65.97M | $-18.32M | $-133.04M | $-15.76M | $-122.80M | $-109.65M | $-106.65M | $-17.11M |
| Low Forecast | $-28.15M | $-26.85M | $-25.91M | $-26.25M | $-30.70M | $-29.39M | $-28.49M | $-28.16M | $-28.32M | $-28.57M | $-27.17M | $-26.18M | $-55.99M | $-48.40M | $-56.09M | $-65.97M | $-27.49M | $-133.04M | $-23.64M | $-122.80M | $-109.65M | $-106.65M | $-25.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.49% | 0.43% | 0.44% | 0.43% | 0.86% | 0.19% | 1.28% | 0.15% | 0.16% | 0.18% | 0.79% |
Solid Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SLDB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Solid Biosciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | 1 | 2 | 1 | 1 | 1 | - | 5 | 11 | 12 | 11 | 10 | 13 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $6.22M | $6.41M | $7.13M | $7.40M | $7.13M | $6.85M | $7.35M | $7.21M | $7.14M | $6.77M | $6.01M |
| Avg Forecast | - | - | - | - | - | - | - | $764.64K | $693.56K | $693.56K | $693.56K | $2.48M | $1.89M | $2.51M | $3.77M | $3.77M | $514.13K | $7.00M | $4.59M | $2.97M | $3.66M | $4.83M | $7.23M |
| High Forecast | - | - | - | - | - | - | - | $764.64K | $693.56K | $693.56K | $693.56K | $2.48M | $1.89M | $2.51M | $3.77M | $3.77M | $514.13K | $7.00M | $4.59M | $2.97M | $3.66M | $4.83M | $8.68M |
| Low Forecast | - | - | - | - | - | - | - | $764.64K | $693.56K | $693.56K | $693.56K | $2.48M | $1.89M | $2.51M | $3.77M | $3.77M | $514.13K | $7.00M | $4.59M | $2.97M | $3.66M | $4.83M | $5.79M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 3.30% | 2.55% | 1.89% | 1.96% | 13.86% | 0.98% | 1.60% | 2.43% | 1.95% | 1.40% | 0.83% |
Solid Biosciences's average Quarter SG&A projection for Mar 24 is $2.48M, based on 1 Wall Street analysts, with a range of $2.48M to $2.48M. The forecast indicates a -60.08% fall compared to SLDB last annual SG&A of $6.22M (Dec 23).
Solid Biosciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | 1 | 2 | 1 | 1 | 1 | - | 5 | 11 | 12 | 11 | 10 | 13 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-1.00 | $-1.05 | $-1.25 | $-1.44 | $-2.61 | $-3.30 | $-3.37 | $-2.49 | $-2.40 | $-2.50 | $-2.84 |
| Avg Forecast | $-0.69 | $-0.66 | $-0.63 | $-0.64 | $-0.75 | $-0.72 | $-0.70 | $-0.69 | $-0.69 | $-0.67 | $-0.66 | $-0.64 | $-1.02 | $-1.18 | $-1.37 | $-1.61 | $-2.66 | $-3.25 | $-2.91 | $-3.00 | $-2.68 | $-2.61 | $-4.86 |
| High Forecast | $-0.69 | $-0.66 | $-0.63 | $-0.64 | $-0.75 | $-0.72 | $-0.70 | $-0.69 | $-0.69 | $-0.63 | $-0.66 | $-0.64 | $-0.55 | $-1.18 | $-1.37 | $-1.61 | $-2.66 | $-3.25 | $-2.91 | $-3.00 | $-2.68 | $-2.61 | $-4.86 |
| Low Forecast | $-0.69 | $-0.66 | $-0.63 | $-0.64 | $-0.75 | $-0.72 | $-0.70 | $-0.69 | $-0.69 | $-0.70 | $-0.66 | $-0.64 | $-1.37 | $-1.18 | $-1.37 | $-1.61 | $-2.66 | $-3.25 | $-2.91 | $-3.00 | $-2.68 | $-2.61 | $-4.86 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.98% | 0.89% | 0.91% | 0.89% | 0.98% | 1.02% | 1.16% | 0.83% | 0.90% | 0.96% | 0.58% |
According to undefined Wall Street analysts, Solid Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SLDB previous annual EPS of $NaN (undefined).
Solid Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| PMVP | PMV Pharmaceuticals | $1.51 | $24.75 | 1539.07% | Buy |
| IPSC | Century Therapeutics | $1.60 | $20.00 | 1150.00% | Buy |
| PASG | Passage Bio | $0.81 | $6.00 | 640.74% | Buy |
| MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
| CABA | Cabaletta Bio | $4.11 | $16.33 | 297.32% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| ACRV | Acrivon Therapeutics | $8.91 | $21.50 | 141.30% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| SLDB | Solid Biosciences | $7.93 | $17.50 | 120.68% | Buy |
| LRMR | Larimar Therapeutics | $7.20 | $14.50 | 101.39% | Buy |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| CCCC | C4 Therapeutics | $6.44 | $11.33 | 75.93% | Hold |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
SLDB Forecast FAQ
Is Solid Biosciences a good buy?
Yes, according to 7 Wall Street analysts, Solid Biosciences (SLDB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of SLDB's total ratings.
What is SLDB's price target?
Solid Biosciences (SLDB) average price target is $17.5 with a range of $12 to $20, implying a 120.68% from its last price of $7.93. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Solid Biosciences stock go up soon?
According to Wall Street analysts' prediction for SLDB stock, the company can go up by 120.68% (from the last price of $7.93 to the average price target of $17.5), up by 152.21% based on the highest stock price target, and up by 51.32% based on the lowest stock price target.
Can Solid Biosciences stock reach $12?
SLDB's average twelve months analyst stock price target of $17.5 supports the claim that Solid Biosciences can reach $12 in the near future.
What are Solid Biosciences's analysts' financial forecasts?
Solid Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $446.18K (high $446.18K, low $446.18K), average EBITDA is $89.24K (high $89.24K, low $89.24K), average net income is $-117M (high $-117M, low $-117M), average SG&A $764.64K (high $764.64K, low $764.64K), and average EPS is $-2.852 (high $-2.852, low $-2.852). SLDB's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-107M (high $-107M, low $-107M), average SG&A $0 (high $0, low $0), and average EPS is $-2.618 (high $-2.618, low $-2.618).
Did the SLDB's actual financial results beat the analysts' financial forecasts?
Based on Solid Biosciences's last annual report (Dec 2021), the company's revenue was $13.62M, beating the average analysts forecast of $10.9M by 24.90%. Apple's EBITDA was $-69.29M, beating the average prediction of $-19.123M by 262.33%. The company's net income was $-72.122M, missing the average estimation of $-360M by -79.99%. Apple's SG&A was $27.14M, beating the average forecast of $18.69M by 45.21%. Lastly, the company's EPS was $-10.13, missing the average prediction of $-13.144 by -22.93%. In terms of the last quarterly report (Jun 2022), Solid Biosciences's revenue was $6.17M, beating the average analysts' forecast of $4.08M by 51.03%. The company's EBITDA was $-21.62M, missing the average prediction of $816.9K by -2746.59%. Solid Biosciences's net income was $-24.802M, missing the average estimation of $-133M by -81.36%. The company's SG&A was $6.85M, missing the average forecast of $7M by -2.13%. Lastly, the company's EPS was $-3.3, beating the average prediction of $-3.25 by 1.54%